Oconee Memorial Hospital
- Type
- Teaching hospital
- Where
- Seneca, SC
- Medicare CCN
- 420009
- Received
- $958,382 in 189 records, 2023 ($150,779 general, $807,603 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: OCONEE MEMORIAL HOSPITAL INC Fuzzy (name and state)
- Lobbying client: OCONEE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 27 | $150,779 |
| 2023 | Research payment | 162 | $807,603 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Epizyme, Inc. | 3 | $633,500 | 2023 |
| National Marrow Donor Program | 17 | $57,415 | 2023 |
| Impulse Dynamics (USA) Inc. | 10 | $45,544 | 2023 |
| Smith+Nephew, Inc. | 2 | $45,000 | 2023 |
| Abbott Laboratories | 13 | $38,153 | 2023 |
| AngioDynamics, Inc. | 1 | $30,000 | 2023 |
| INSTYLLA, INC. | 7 | $29,129 | 2023 |
| Eli Lilly and Company | 2 | $27,391 | 2023 |
| Philips North America LLC | 1 | $16,656 | 2023 |
| Contego Medical, Inc | 4 | $12,170 | 2023 |
| ZOLL Circulation Inc | 5 | $8,284 | 2023 |
| BioNTech SE | 10 | $6,150 | 2023 |
| Novo Nordisk AS | 108 | $4,108 | 2023 |
| Cook Incorporated | 3 | $2,935 | 2023 |
| Genentech, Inc. | 1 | $1,500 | 2023 |
| Stryker Corporation | 2 | $446 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 162 | $807,603 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 17 | $57,415 |
| Grant | 5 | $47,935 |
| Long term medical supply or device loan | 3 | $30,446 |
| Debt forgiveness | 1 | $13,483 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | AngioDynamics, Inc. | $30,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2023 | |
| 2023-12-31 | Stryker Corporation | $389 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-31 | Stryker Corporation | $56 | Long term medical supply or device loan | In-kind items and services | SURGISTOOL Device, PATIENT HANDLING - PH | 2023 | |
| 2023-12-13 | INSTYLLA, INC. | $4,250 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-12-12 | Abbott Laboratories | $13,483 | Debt forgiveness | Cash or cash equivalent | ASSURITY Device, Cardiac Rhythm Management | 2023 | |
| 2023-12-12 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | MorningSun | 2023 | |
| 2023-12-01 | Contego Medical, Inc | $2,080 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2023 |
| 2023-11-29 | Philips North America LLC | $16,656 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2023 |
| 2023-11-27 | Novo Nordisk AS | $2,000 | Research payment | Cash or cash equivalent | NN7415-4807 | 2023 | |
| 2023-11-27 | Novo Nordisk AS | $607 | Research payment | Cash or cash equivalent | NN7415-4807 | 2023 | |
| 2023-11-21 | Epizyme, Inc. | $34,000 | Research payment | In-kind items and services | Tazverik Drug, Oncology | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | 2023 |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-11-09 | Impulse Dynamics (USA) Inc. | $376 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-10-20 | Contego Medical, Inc | $7,800 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2023 |
| 2023-10-20 | National Marrow Donor Program | $4,620 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-06 | Cook Incorporated | $1,568 | Grant | In-kind items and services | ROADRUNNER UNIGLIDE Device, PI - WIRE GUIDES | 2023 | |
| 2023-10-06 | Cook Incorporated | $1,167 | Grant | In-kind items and services | CXI Device, PI - SPECIALTY CATHETERS | 2023 | |
| 2023-10-06 | Cook Incorporated | $200 | Grant | In-kind items and services | BENTSON Device, PI - WIRE GUIDES | 2023 | |
| 2023-10-05 | Abbott Laboratories | $3,900 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2023 |
| 2023-10-05 | Abbott Laboratories | $1,600 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2023 |
| 2023-09-26 | Eli Lilly and Company | $26,509 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC | 2023 | |
| 2023-09-18 | Abbott Laboratories | $2,400 | Research payment | Cash or cash equivalent | ABT NG DES 48 EECSS Device, Vascular | A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent | 2023 |
| 2023-09-12 | BioNTech SE | $5,520 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-09-07 | Abbott Laboratories | $1,285 | Research payment | Cash or cash equivalent | XIENCE V Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2023 |
| 2023-09-03 | Impulse Dynamics (USA) Inc. | $11,288 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-09-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-08-29 | Abbott Laboratories | $1,785 | Research payment | Cash or cash equivalent | ABT NG DES 48 EECSS Device, Vascular | A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent | 2023 |
| 2023-08-04 | National Marrow Donor Program | $8,535 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-03 | Impulse Dynamics (USA) Inc. | $4,954 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-08-02 | ZOLL Circulation Inc | $2,800 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | ISOSHOCK | 2023 |
| 2023-08-01 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Xience Skypoint Device, Vascular | XIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS) | 2023 |
| 2023-08-01 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Xience Skypoint Device, Vascular | XIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS) | 2023 |
| 2023-08-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-07-12 | INSTYLLA, INC. | $1,000 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-07-03 | Impulse Dynamics (USA) Inc. | $351 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-07-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-06-30 | National Marrow Donor Program | $5,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $4,095 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $3,880 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $3,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $3,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $3,160 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $3,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $2,820 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $2,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $2,765 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $1,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $1,730 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $1,380 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-30 | National Marrow Donor Program | $1,065 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-21 | INSTYLLA, INC. | $2,000 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-14 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-06-13 | Smith+Nephew, Inc. | $33,750 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-06-13 | Smith+Nephew, Inc. | $11,250 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-06-03 | Impulse Dynamics (USA) Inc. | $5,596 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-06-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-05-25 | INSTYLLA, INC. | $4,879 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-05-18 | Abbott Laboratories | $7,600 | Research payment | Cash or cash equivalent | Xience Skypoint Device, Vascular | XIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS) | 2023 |
| 2023-05-10 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | ABT NG DES 48 EECSS Device, Vascular | A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent | 2023 |
| 2023-05-03 | Impulse Dynamics (USA) Inc. | $7,959 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-05-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-04-26 | ZOLL Circulation Inc | $4,884 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | ISOSHOCK | 2023 |
| 2023-04-26 | INSTYLLA, INC. | $1,000 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-04-25 | Epizyme, Inc. | $34,000 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | 2023 |
| 2023-04-24 | Novo Nordisk AS | $607 | Research payment | Cash or cash equivalent | NN7415-4807 | 2023 | |
| 2023-04-12 | Impulse Dynamics (USA) Inc. | $7,315 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-04-11 | Epizyme, Inc. | $565,500 | Research payment | In-kind items and services | Tazverik Drug, Oncology | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | 2023 |
| 2023-04-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-03-29 | Impulse Dynamics (USA) Inc. | $1,125 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-03-23 | Contego Medical, Inc | $1,250 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2023 |
| 2023-03-23 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | DRAGONFLY OPSTAR Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2023 |
| 2023-03-23 | Abbott Laboratories | $325 | Research payment | Cash or cash equivalent | DRAGONFLY OPSTAR Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2023 |
| 2023-03-22 | INSTYLLA, INC. | $1,000 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-03-15 | Eli Lilly and Company | $882 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-03-08 | Impulse Dynamics (USA) Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | 2023 | |
| 2023-03-05 | Impulse Dynamics (USA) Inc. | $5,080 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2023 |
| 2023-03-01 | Abbott Laboratories | $1,375 | Research payment | Cash or cash equivalent | DRAGONFLY OPSTAR Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2023 |
| 2023-03-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-02-10 | Contego Medical, Inc | $1,040 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2023 |
| 2023-02-08 | INSTYLLA, INC. | $15,000 | Research payment | Cash or cash equivalent | INSTYLLA MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2023 |
| 2023-02-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 | |
| 2023-01-11 | ZOLL Circulation Inc | $200 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | ISOSHOCK | 2023 |
| 2023-01-09 | ZOLL Circulation Inc | $200 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | ISOSHOCK | 2023 |
| 2023-01-09 | ZOLL Circulation Inc | $200 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | ISOSHOCK | 2023 |
| 2023-01-01 | BioNTech SE | $70 | Research payment | Cash or cash equivalent | Pre-commercial | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Seneca, SC, county Oconee County, SC, state South Carolina; placed by its city name.
| Measure | Place (city or town) Seneca, SC | County Oconee County, SC | State South Carolina |
|---|---|---|---|
| Population B01003 | 8,993 | 80,469 | 5,296,225 |
| Population, 2020 census P1 | 8,850 | 78,607 | 5,118,425 |
| Median age B01002 | 39.6 | 47.3 | 40.2 |
| Under 18 B01001 | 18.5% | 19.1% | 21.4% |
| 65 and over B01001 | 20.4% | 24.9% | 18.9% |
| Households B11001 | 4,082 | 34,515 | 2,117,989 |
| Foreign born B05002 | 2.6% | 4.2% | 5.8% |
| Median household income B19013 | $52,022 | $62,388 | $69,324 |
| Median family income B19113 | $74,864 | $80,443 | $86,707 |
| Per capita income B19301 | $34,204 | $39,360 | $39,236 |
| Poverty rate B17001 | 22.1% | 17.6% | 14.1% |
| Unemployment rate B23025 | 8.9% | 5.9% | 4.9% |
| Civilian labor force B23025 | 4,606 | 35,647 | 2,560,429 |
| Mean commute (minutes) B08013 | 16.0 | 23.9 | 25.6 |
| Bachelor's degree or higher B15003 | 29.1% | 28.7% | 32.1% |
| Housing units B25001 | 4,648 | 42,100 | 2,443,039 |
| Owner-occupied B25003 | 51.4% | 76.2% | 71.9% |
| Renters B25003 | 48.6% | 23.8% | 28.1% |
| Median home value B25077 | $240,000 | $237,100 | $259,000 |
| Median gross rent B25064 | $807 | $881 | $1,180 |
| White, not Hispanic B03002 | 72.8% | 83.1% | 61.9% |
| Black B03002 | 17.4% | 5.2% | 24.6% |
| Hispanic or Latino B03002 | 6.4% | 6.2% | 7.4% |
| Asian B03002 | 0.8% | 0.7% | 1.7% |
| American Indian and Alaska Native B03002 | 0.8% | 0.4% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Seneca, SC.
Comments